Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate...
Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing.
From other sites
at Nasdaq.com (Fri, 10:51AM)
at 4-traders.com (Mar 23, 2015)
at Zacks.com (Mar 13, 2015)
at MarketWatch.com (Mar 11, 2015)
at CNBC.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs